Sodium-Glucose Cotransporter 2 Inhibitors Tied to Lower Kidney Stone Risk
By Lori Solomon HealthDay Reporter
THURSDAY, Feb. 8, 2024 -- For adults with type 2 diabetes, initiation of sodium-glucose cotransporter 2 inhibitors (SGLT2is) may lower the risk for nephrolithiasis, according to a study published online Jan. 29 in JAMA Internal Medicine.
Julie M. Paik, M.D., Sc.D., M.P.H., from Brigham and Women’s Hospital in Boston, and colleagues examined the association between SGLT2is and the risk for developing nephrolithiasis in patients with type 2 diabetes. The analysis included 358,203 propensity-matched pairs initiating an SGLT2i or a glucagon-like peptide 1 receptor agonist (GLP-1RA) and 331,028 propensity-matched pairs initiating an SGLT2i or a dipeptidyl peptidase 4 inhibitor (DPP4i).
The researchers found that during a median follow-up of 192 days, the risk for nephrolithiasis was lower in patients initiating an SGLT2i versus those initiating a GLP-1RA (14.9 versus 21.3 events per 1,000 person-years; hazard ratio [HR], 0.69; rate difference [RD], −6.4) or a DPP4i (14.6 versus 19.9 events per 1,000 person-years; HR, 0.74; RD, −5.3). Similar associations between SGLT2i use and nephrolithiasis risk were seen by sex, race and ethnicity, history of chronic kidney disease, and obesity. Among adults aged younger than 70 years, the magnitude of the risk reduction with SGLT2i use was larger than for those aged 70 years or older (HR, 0.85; RD, −3.46 per 1,000 person-years).
"Our findings could help inform clinical decision-making for patients with diabetes who are at risk for developing kidney stones," Paik said in a statement.
Several authors disclosed ties to industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
AI-Informed Health App Aids Diabetes Outcomes
WEDNSDAY, May 15, 2024 -- Use of an artificial intelligence (AI)-informed health app aids diabetes outcomes and cuts atherosclerotic cardiovascular disease (ASCVD) risk, according...
Four in 10 Adults With Diabetes Report Taking a GLP-1 Receptor Agonist
TUESDAY, May 14, 2024 -- One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using...
Fat-Enlarged Axillary Nodes on Mammogram May Indicate Higher CVD Risk
TUESDAY, May 14, 2024 -- Fat-enlarged axillary nodes on screening mammograms can predict the risk for cardiovascular disease (CVD), according to a study presented at the annual...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.